2026-08-29T14:17:46Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/183622024-11-28T15:00:12Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16971col_20.500.12105_16977

00925njm 22002777a 4500 dc Franco, Fernando author Carcereny, Enric author Guirado, Maria author Ortega, Ana L. author López-Castro, Rafael author Rodríguez-Abreu, Delvys author García-Campelo, Rosario author Del Barco, Edel author Juan, Oscar author Aparisi, Francisco author González-Larriba, Jose L. author Domine, Manuel author Trigo, Jose M. author Cobo, Manuel author Cerezo, Sara author Calzas, Julia author Massutí, Bartomeu author Bosch-Barrera, Joaquim author García Coves, Paola author Domènech, Marta author Provencio, Mariano author 2021-06-02 Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce. Patients and methods This was an observational multicenter study that enrolled patients with lung cancer and tho racic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demo graphic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed. Results With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty per cent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overallsurvival was 9.5 months (95% CI 8.8–10.2 months), with an estimated rate of 70.3% (95% CI 67.2–73.4%), 38.9% (95% CI 35.4–42.4%), and 14.8% (95% CI 11.8–17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mor tality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1–2. Long-term survival (> 2 years) was confirmed in 6.6% of patients,showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis. Conclusion This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients. 10.1371/journal.pone.0251761 1932-6203 PLOS ONE http://hdl.handle.net/10668/4053 34077442 http://hdl.handle.net/20.500.12105/18362 Epidemiology Treatment Survival Small cell lung cancer Spain Thoracic tumor Epidemiología Terapéutica Supervivencia (salud pública) Carcinoma pulmonar de células pequeñas España Neoplasias torácicas Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry